Mirum Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MIRM | IONS | TVTX | ARWR | BMRN | RARE | |
|---|---|---|---|---|---|---|
| Market cap | 6.30B | 6.67B | 5.03B | 8.71B | 11.06B | 1.69B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -570.4 | -35.0 | 9.9 | -12.4 | 9.0 | 76.1 |
| Price/book | 16.0 | 15.1 | 222.1 | 18.7 | 1.8 | -5.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +24.17% | −45.88% | +46.53% | +47.68% | +5.42% | −47.82% |
| Today | +11.42% | −0.67% | +6.09% | +3.56% | +2.64% | +3.19% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MIRM news ›Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 3, 2026 4:01pm EST - Q3 2026 net product sales of $185.7 million; 2026 net product sales guidance increased to $715 million to $720 million - Received U.S. FDA approval of and launched ATEBRIOZ® for FOP - Announced three positive…
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, Citizens Jmp Analyst Says
Posted by Danessa Lincoln on Nov 4th, 2026 Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) had its target price increased by investment analysts at Citizens Jmp from $144.00 to $167.00 in a note issued to investors on Wednesday,…
Mirum outlines $715M to $720M 2026 net product sales guidance while targeting cash flow positive next year
Mirum Q3 2026 earnings: raised sales guidance, LIVMARLI growth, Atebrioz launch, and key pipeline catalysts. Earnings Call Insights: Mirum Pharmaceuticals (MIRM) Q3 2026 - "Third quarter was another strong period for Mirum, both…
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call November 3, 2026 4:30 PM EST Andrew McKibben - Senior Vice President, Strategic Finance & Investor RelationsChristopher Peetz - CEO & DirectorPeter Radovich - COO & PresidentRob…
More from 1 other outlet
Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Earnings Results
Posted by Michael Walen on Nov 3rd, 2026 Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus…
EBITDA of Miro Sciences Ltd – ASX:MSX
Miro Sciences Ltd. engages in researching and developing biomedical products targeting neurodegenerative conditions. It's research and development program is focused on developing a treatment for stroke-related brain injury and dementia or…
Average basic shares outstanding of Miro Sciences Ltd – FWB:NBM0
Miro Sciences Ltd. engages in researching and developing biomedical products targeting neurodegenerative conditions. It's research and development program is focused on developing a treatment for stroke-related brain injury and dementia or…
Non-controlling/minority interest of Miro Sciences Ltd – ASX:MSX
Miro Sciences Ltd. engages in researching and developing biomedical products targeting neurodegenerative conditions. It's research and development program is focused on developing a treatment for stroke-related brain injury and dementia or…
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leading rare disease company, today announced positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ™ (zilurgisertib), an oral activin receptor-like kinase 2 (ALK2) inhibitor,…
Mirion Technologies, Inc. $MIR Stake Cut by Schwartz Investment Counsel Inc.
Posted by Danessa Lincoln on Oct 28th, 2026 Here are the key news stories impacting Mirion Technologies this week: Shares of MIR stock opened at $15.33 on Wednesday. Mirion Technologies, Inc. has a fifty-two week low of $14.04 and a…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com9
- tradingview.com7
- seekingalpha.com5
- defenseworld.net3
- financialcontent.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 33 articles, not a forecast.